differentiate NASH and simple steatosis based on a single Fibroscan examination (liver stiffness and controlled attenuation parameter (CAP)).
Methods:
Patients with suspected NAFLD prospectively underwent FibroScan examination within 2 weeks of a standard of care liver biopsy (LB) between March 2014 and January 2016 at seven UK centers. LB were read in a blinded manner by two expert pathologists. NASH was diagnosed using the FLIP algorithm. NASH severity was graded according to the NAS score. To develop a score to diagnose NASH the cohort was split randomly into training (80%) and validation (20%) sets. years. 67% were male, 82% had a NAS score ≥3 and 71% had NASH, 91% had a reliable Fibroscan examination. Performance of the scores is shown in the table.
Conclusion:
A novel score based on measurement of liver stiffness and CAP from a single FibroScan examination was able to correctly classify 79% of patients with/without NASH as well as correctly staging severity in 86%. This has promise as a non-invasive marker for detecting/staging disease activity in patients with NASH.
